Introduction
A growing number of studies have been performed over decades for pharmacological verification of the effects of flavonoids, which are believed to be beneficial for good health [1] [2] [3] [4] . Flavonoid aglycones exert multiple effects such as anti-oxidation, -inflammation, and -cancer in vivo and in vitro. Flavonoid glucuronides can be potent precursors of the biologically active aglycones but do not always show biological activities similar to aglycones [5] [6] [7] . However, due to their metabolism in the body, aglycones comprise a very small concentration in the plasma of human and animals after oral administration, and glucuronides and/or sulfateconjugates are the main circulating metabolites of flavonoids [8] [9] [10] [11] [12] [13] . Due to chemical and structural differences between aglycones and glucuronides in terms of size, solubility, and polarity, flavonoid glucuronides are generally understood to be unable to pass through the cellular membranes of the lipid bilayer and to cross the vascular lumen to extravascular spaces. The path to an active aglycone, b-glucuronidase, which exists in macrophages and deconjugates flavonoid glucuronides to active aglycones, has been elucidated. The function of b-glucuronidase has been actively demonstrated in the field of cardiology using quercetin, which has strong anti-oxidant and -inflammation effects [6, 7] . Because various types of flavonoids show biological effects on immune responses, the metabolism of flavonoids is thought to play biological roles in detoxification and excretion of foreign substances.
Jumihaidokuto (JHT) is a pharmaceutical-grade traditional Japanese medicine prescribed to patients with inflammatory dermatoses. We previously demonstrated the blood pharmacokinetics of the flavonoids identified in JHT, showing that various types of flavonoid glucuronides appeared in the plasma of rats given JHT orally [13] . In particular, genistein 7-O-glucuronide (GEN7G), liquiritigenin 7-O-glucuronide (LQG7G), liquiritigenin 4 0 -Oglucuronide (LQG4 0 G), and hesperetin 7-O-glucuronide (HPT7G) were identified in the plasma, although concentrations of their aglycones were extremely low. We moreover found that JHT suppressed Propionibacterium acne-induced dermatitis by modulating macrophage functions [14] . These observations suggested a relationship between the effect of JHT on macrophage activation and the metabolism of flavonoids.
In this study, we hypothesized that the flavonoids generated by JHT administration augment the macrophage functions in skin infection. We first examined the pharmacological profiles of GEN7G focusing on interaction with macrophages in vivo and in vitro. The results of the present study showed that flavonoid glucuronides play roles as a carrier and a precursor of bioactive aglycones, and that flavonoids can enhance macrophage functions through agonistic potentials on the nuclear estrogen receptor (ER).
Materials and Methods

Test compounds
Genistein, liquiritigenin, and hesperetin were purchased from Wako Pure Chemical Industries (Osaka, Japan). Genistein 7-O-glucuronide (GEN7G) and hesperetin 7-O-glucuronide (HPT7G) were purchased from Toronto Research Chemical Industries (Toronto, ON). Liquiritigenin 4 0 -O-glucuronide (LQG4 0 G) and liquiritigenin 7-O-glucuronide (LQG7G) with purities high enough to be evaluated in biological tests were supplied by Tsumura & Co (Tokyo, Japan). The chemical structures of these flavonoids are shown in Supplemental Figure S1 . Estradiol (Sigma-Aldrich, St. Louis, MO) was used as a reference.
Pseudoinfection model
Male ICR mice were purchased from Charles River Laboratories Japan (Kanagawa, Japan), allowed housed at a temperature of 23 AE 38C, relative humidity of 50 AE 20%, and a 12 h light:12 h dark cycle with lights on from 07:00 to 19:00 h daily with free access to water and standard laboratory food. All experimental procedures were approved by and conducted according to the guidelines of the experimental animal ethics committees of Tsumura & Co.
Particles of FITC-conjugated and killed Staphylococcus aureus (FITC-S. aureus) (Molecular Probes, Eugene, OR) were suspended in saline, and injected intradermally into the dorsal side of the ear at 67 mg/10 ml/site using a microsyringe (Hamilton Co., Reno, NV) under inhaled isoflurane anesthesia [14] .
Measurement of genistein and GEN7G in pseudoinfection model
GEN7G was injected intravenously into mice at 1 mg/kg in saline immediately and 3 h after pseudoinfection. The mice were exsanguinated 6 h after pseudoinfection, followed by dissection of the ears, and their homogenization in 50 mmol/L Tris-HCl (pH 8.3) containing 20 mmol/L of saccharic acid 1, 4-lactone (Santa Cruz Biotech., Santa Cruz, CA), which is a b-glucuronidase inhibitor. The samples were stored at À808C until measurement of genistein and GEN7G by LC-MS/MS as described below [13] . For quantification of both compounds in the homogenized tissues, a portion of the homogenized tissue was diluted with water, mixed with an internal standard (niflumic acid; Sigma-Aldrich), and the solid phase was extracted by using a Sep-Pak Vac (Waters, Milford, MA). The cartridge was conditioned with 2 mL of methanol and water before use. The diluted solution was loaded into the preconditioned columns, washed with 0.8 mL of water, and eluted with 0.8 mL of methanol. The eluent was collected and dried using a centrifugal evaporator and concentration system (CC-105; Tomy Seiko Co., Tokyo, Japan). The residue was dissolved in the HPLC mobile phase and injected into an LC-MS/MS system. For quantification of genistein and GEN7G in the culture fluids, a portion of them was diluted with water and mixed with internal standard solution and ethyl acetate, and the solution was centrifuged at 7000g for 5 min. The supernatant was dried and concentrated under a stream of nitrogen gas. The residue was diluted with the HPLC mobile phase and injected into the LC-MS/MS system. HPLC separation of genistein and GEN7G was performed using an Agilent 1100 system (Agilent Technologies, Santa Clara, CA), which consisted of a vacuum degasser and a quaternary pump for solvent and sample delivery. A Kinetex PFP column (100 Â 2.1 mm I.D., 2.6-mm particle size; Phenomenex, Torrance, CA) was used to separate each analyte for LC-MS/MS at 408C. The mobile phase consisted of solution A (0.2 vol% acetic acid) and solution B (acetonitrile containing 0.2 vol% acetic acid) with a gradient of solution B (0-10 min, 11%; 10-30 min, 11-40%; 30-30.01 min, 40-90%; 30.01-35 min, 90%; 35-35.01 min, 90-11%; 35.01-40 min, 11%; v/v) at a flow rate of 0.35 mL/min. The HPLC system was interfaced with an API4000 triple quadrupole mass spectrometer (AB Sciex, Framingham, MA). The mass spectrometric analyses were conducted using electrospray ionization operating in negative ionization mode using the following multiple reaction monitoring (MRM) mass transitions (m/z): 268.919/132.7 (genistein) and 445.072/269.1 (GEN7G). The declustering potential was set at À105 or À85 V, the collision energy was set at À42 or À30 V, and collision cell exit potential was set at À21 or À19 V for analyses of genistein and GEN7G, respectively. Other parameters were set as follows: curtain gas, 40; ion-spray voltage, À4500 V; temperature, 6008C; ion source gas 1, 50 psi; ion source gas 2, 40 psi; and collision-activated dissociation gas, 6 psi.
E v a l ua t i o n o f p h a go c y t os i s a c t i v i t y in pseudoinfection model
The phagocytosis of immune cells in the inflamed ears was evaluated according to the report published previously with a minor modification [15] . GEN7G was injected intravenously into mice at 1 mg/kg in saline immediately and 3 h after the bacterial injection. The ears were dissected 6 h post and cut into nine pieces, followed by enzymatic digestion in PBS containing 0.45 mg/mL dispase I (Rosche Diagnostics, Indianapolis, IN), 2 mg/mL collagenase II (Sigma-Aldrich), and 0.32 mg/mL DNase I (Sigma-Aldrich) for 2 h while shaking at 378C. Single-cell suspensions were prepared by mechanical disruption in ice-cold DMEM supplemented with 10% FBS, followed by filtration through a 70-mm cell strainer. After centrifugation twice, cells were gently suspended in 30% Percoll (GE Healthcare, Piscataway, NJ), and then centrifuged at 630g for 20 min to isolate and remove sebaceous, low-density cells, and debris. Cell pellets were resuspended in DMEM and passed through a 40-mm cell strainer. After centrifugation, cells were fixed with paraformaldehyde and stored at 48C until flow cytometric analysis. After blocking non-specific binding using mouse 
Macrophage assays
Mouse macrophage RAW264.7 cells (ATCC, Manassas, VA) were grown in DMEM supplemented with 10% heatinactivated fetal bovine serum, 4.5 g/L glucose, 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 10 mmol/L HEPES. Cells were seeded in 96-well culture plates at 5-20 Â 10 3 cells/well, and cultured with the test compound (1-30 mmol/L) in the presence or absence of a suboptimal dose of 0.5 ng/mL mouse IFN-g (PeproTech, Rocky Hill, NJ). One to three days after incubation in a 5% CO 2 -gas incubator, cells were harvested and analyzed by phagocytosis or cell-surface antigen expression assay.
To evaluate phagocytic activity, FITC-S. aureus prepared in the medium described above was added at a final concentration of 30 mg/mL after removal of culture fluids. After 30 min incubation in a 5% CO 2 -gas incubator, cells were harvested using cold PBS containing 2 mmol/L EDTA, washed, and treated for 15 min with phosphate buffer containing 4% paraformaldehyde (pH 7.4). FITC-positive cells were quantified by FACS. Activity was indicated as mean fluorescent intensity (MFI) of whole cells. Some tests were done in the presence of the b-glucuronidase inhibitor 1-
In assays to measure cell-surface antigen expression, the harvested cells were treated with anti-CD16/32 antibody, followed by incubation on ice for 20 min with FITC-labeled anti-mouse CD86 (clone: GL1) purchased from BD Biosciences, APC-labeled anti-mouse CD192 (clone: SA203G11), PE/Cy7-labeled anti-mouse CD11b (clone: M1/70), or CD88 (clone: 20/70), which were all purchased from BioLegend. After washing, cells were treated for 15 min with phosphate buffer containing 4% paraformaldehyde, and analyzed using the FACS system. Levels of expression of cell-surface antigen were all indicated as MFI. Fluorescent-labeled isotype-matched control antibodies (BD Biosciences and BioLegend) were used in this study, confirming that the antibodies showed specific binding.
Assays of interaction with estrogen receptors
Binding assays from Eurofins Panlabs Taiwan Ltd. (Taipei, Taiwan) were performed targeting human nuclear estrogen receptors. Human estrogen receptor-a (ERa) and estrogen receptor-b (ERb) expressed in Sf9 insect cells were prepared individually in modified Tris-HCl buffer pH 7.4. An aliquot of 9.6 ng (ERa) or 7.5 ng (ERb) was incubated with 0.5 nmol/L [ 3 H]-estradiol for 2 h at 258C. Non-specific binding was estimated in the presence of 1 mmol/L diethylstilbestrol. Receptor proteins were filtered and washed, and the filters were then counted to determine specifically bound [ 3 H]-estradiol. The specific binding was defined by subtracting nonspecific binding from total binding, and expressed as the percentage inhibition using the following formula:
Â 100, where ''a'' is the average cpm of nonspecific binding, ''b'' is the average cpm of total binding, and ''c'' is the average cpm in the presence of the test substance. The binding specificities of these procedures were approximately 85% (ERa) and 90% (ERb). The half maximal inhibitory concentration (IC 50 ) of test samples was calculated.
A PathHunter b-arrestin assay provided by DiscoveRx Corp. (Fremont, CA) was performed using CHO-K1 cells engineered to coexpress ProLink-tagged GPR30, which is called human G-coupled estrogen receptor 1, and b-galactosidase acceptor-tagged b-arrestin. The cells were seeded in 384-well microplates and incubated with test samples for 90-180 min, followed by incubation with the PathHunter detection reagent cocktail for 1 h. Chemiluminescent signals were measured using a PerkinElmer EnVision reader, and evaluated using the CBIS data analysis suite (ChemInnovation Software Inc., San Diego, CA). The percentage activity was calculated using the following formula: activity (%) ¼100 Â (mean relative luminescent units (RLU) of test sample-mean RLU of vehicle control)/(mean RLU of vehicle control). Mean RLU of positive and negative controls were 2,178,667 and 648,267, respectively. Particles of FITC-conjugated and killed S. aureus (67 mg/10 ml/site) were injected intradermally into the ears of mice. Genistein 7-O-glucuronide (GEN7G) dissolved in saline was administrated intravenously to the mice at a dose of 1 mg/10 ml/kg immediately and 3 h post pseudoinfection. The ears were cut off 6 h post pseudoinfection, and digested in a mixture of three enzymes (dispase I, collagenase II, and DNase I) for 2 h at 378C, followed by preparation of single cells. Phagocytic cells were stained by anti-mouse Ly6G and anti-mouse CD11b, and analyzed by flow cytometry using an FACSaria II system. Cell numbers and mean fluorescent intensity (MFI) of FITC in neutrophils (CD11b 
Measurement of concentration and enzymatic activity of b-glucuronidase
Total RNA was prepared from proliferating RAW264.7 cells cultured in 24-well plates, followed by preparation of cDNAs. A TaqMan gene expression assay was performed using TaqMan primers for Gusb (bglucuronidase) and a housekeeping gene, Gapdh (glyceraldehyde-3-phosphate dehydrogenase), which were purchased from ABI Biosystems (Foster City, CA). To measure the amount of b-glucuronidase in a level of protein, culture fluids and lysates of RAW264.7 cells and homogenizations of the mouse skins were centrifuged at 10,000g for 20 min at 48C, and stored at À808C. b-glucuronidase was quantified using ELISA kits according to the manufacturer's instructions (CloudClone Corp., Houston, TX). Total protein was measured by the Bradford assay (Bio-Rad, Hercules, CA) using bovine serum albumin as a standard. Determinations of b-glucuronidase were compensated and are indicated as relative amounts.
To examine b-glucuronidase activity, GEN7G was added as a substrate at a final concentration of 30 mmol/L to live RAW264.7 cells seeded at 1 Â 10 5 cells/ 0.5 mL/well in 24-well plates, or its lysates. After 24 h incubation in a 5% CO 2 -gas incubator, the culture fluids or lysates were harvested and stored at À808C until measurement of genistein and GEN7G by LC-MS/MS as described above. 
Statistical analysis
All values are expressed as the mean AE SEM. Statistical significance was evaluated by one-way analysis of variance (ANOVA) or two-way repeated measures ANOVA, followed by Dunnett's multiple comparisons or unpaired Student's t-test. A probability of less than 0.05 was considered significant.
Results
Flavonoid glucuronide GEN7G is converted to aglycone genistein in inflamed mouse skin
It is well demonstrated that oral administration of genistein exerts a variety of biological effects and that genistein is conjugated predominantly to GEN7G in the gut, as reported elsewhere [16] . Using a mouse model of skin inflammation in which FITC-labeled S. aureus was injected intradermally into the ears, we first examined whether genistein was detectable in the inflamed skin after intravenous injection of GEN7G. Both genistein and GEN7G were detected in both bacteria-injected inflamed skin and non-injected normal skin (Fig. 1) . The amount of genistein was 2.5 times higher in the inflamed skin (0.843 ng/ear) than in the non-injected skin (0.338 ng/ear). On the other hand, the concentration of GEN7G was slightly lower in inflamed skin than in noninflamed skin, though the difference was not statistically significant. No genistein was found in the skin of normal mice without genistein injection (data not shown).
We evaluated the effect of GEN7G on phagocytosis using immune cells in vivo. To quantitate numbers, populations, and phagocytic activity of monocytes/macrophages (CD11b þ Ly6G À ) and neutrophils (CD11b
in the inflamed ears, FACS analysis was performed at 6 h post pseudoinfection in mice injected with GEN7G intravenously. The bacteria inoculation (Control and GEN7G) did not alter the total number of CD11b þ Ly6G
À cells compared to normal skin (normal). The MFI of FITC in FITC-positive CD11b þ Ly6G À cells, which represent the monocytes/macrophages ingesting FITC-labeled bacteria, were significantly higher in GEN7G-treated group than in the Control (Table 1 and representative blots are shown in Supplemental Fig. S2 ). In contrast, the MFI of FITC in CD11b þ Ly6G þ cells (neutrophils) were not significantly different between bacteria-injected control and GEN7G-treated groups, though the cell numbers and phagocytic activity of CD11b þ Ly6G þ cells were clearly increased in the pseudoinfection model. These findings suggest an adjuvant effect of GEN7G on enhancing phagocytic response of macrophages in vivo.
Flavonoid glucuronides GEN7G and LQG7G enhanced macrophage phagocytosis and functional receptor expression
To investigate the bioactive characteristics of GEN7G in the macrophage culture systems, we examined and compared various types of flavonoid glucuronides that had been quantified in the plasma of rats given orally with JHT 13 , as well as their aglycones, genistein, liquiritigenin, and hesperetin. As shown in Table 2 , GEN7G and LQG7G as well as their aglycones significantly enhanced phagocytosis in RAW264.7 cells in the presence of a suboptimal dose of IFN-g (0.5 ng/mL), while LQG4 0 G, HPT7G, and hesperetin did not. GEN7G, which showed the highest activity among the four tested flavonoid-glucuronides, enhanced the phagocytic activity of RAW264.7 cells in a dose-and time-dependent manner up to three days ( Fig. 2A and B) . We also observed that addition of GEN7G and its aglycone genistein turned cell morphology of RAW264.7 cells to be more adhesive and spindle shaped in the presence of IFN-g (Fig. 3) .
We next performed flow cytometric analysis of the following functional receptors on RAW264.7 cells: chemotactic receptor CD192 for monocyte chemoattractant protein-1 (MCP-1), complement receptors CD88, and CD11b for components C5a and iC3b, respectively, and costimulatory molecule CD86. Three-day culture in the presence of GEN7G or LQG7G increased their expression, while LQG4 0 G and HPT7G were inactive (Table 3) . Again, parallel to the GEN7G and LQG7G effects on RAW264.7 cells, their aglycone forms genistein and liquiritigenin but not hesperetin increased the functional antigens.
Flavonoid-glucuronide GEN7G enhanced macrophage phagocytosis in a nuclear estrogen receptor-dependent manner Because genistein and liquiritigenin are reported to bind to nuclear estrogen receptors (ERs) [17, 18] , we investigated the involvement of nuclear ERs in flavonoid effects on macrophages. Addition of the nuclear ER antagonist ICI-182780 significantly suppressed phagocytosis and abolished the increase in CD88 expression induced by GEN7G (Fig. 4A and B) . In contrast, the nuclear ER agonist estradiol enhanced phagocytosis at concentrations similar to those of GEN7G and genistein (Fig. 4C) .
Flavonoid aglycones genistein and liquiritigenin but not glucuronides GEN7G and LQG7G directly bind to nuclear estrogen receptors
Competitive binding assays were performed to examine direct binding of flavonoid glucuronides and aglycones to human ERs. The IC 50 s of genistein, liquiritigenin, and hesperetin were 0.053, 1.11, and >100 mmol/L in the ERa binding assay, and 0.010, 0.22, and 52.5 mmol/L in the ERb binding assay, respectively (Fig. 5A, B, and D) . On the other hand, the IC 50 s of GEN7G, LQG7G, and LQG4 0 G were more than 30 mmol/L in both ERa and ERb binding assays. We further examined the interaction of flavonoids with membraneassociated GPR30, one of the G-protein-coupled estrogen receptor (GPERs). As shown in Fig. 5C and D, genistein did not exhibit agonistic activity toward GPR30 as shown by a reduction of the basal signal following b-arrestin recruitment. GEN7G also did not exert a reaction against human GPR30 even at the high concentration of 100 mmol/L. These findings suggested that the aglycones genistein and liquiritigenin, but not the glucuronides GEN7G and LQG7G, could directly bind to ERa and ERb but not to membrane-associated GPR30.
Macrophages express b-glucuronidase and convert flavonoid glucuronides GEN7G to aglycones genistein
These lines led us to hypothesize that a deconjugation process of the glucuronides GEN7G and LQG7G to the aglycones genistein and liquiritigenin, respectively, is required for flavonoids to enhance macrophage phagocytosis. We examined and confirmed that RAW264.7 cells expressed b-glucuronidase at the levels of messenger RNA and protein (Fig. 6A and B) . We also detected b-glucuronidase in mouse whole skin (Fig. 6B) . We next examined whether b-glucuronidase in RAW264.7 cells can deconjugate GEN7G to genistein. As shown in Figure 7 , incubation of GEN7G in the presence of live cells or homogenized cell lysates converted GEN7G to genistein. The skin homogenate also showed a similar conversion of GEN7G to genistein (data not shown). To verify the involvement of the deconjugation process in the macrophage activation induced by GEN7G, a b-glucuronidase inhibitor was added to the cultures. The conversion to genistein in RAW264.7 cells was reduced to half by the b-glucuronidase inhibitor (Fig. 8A) . The b-glucuronidase inhibitor completely abolished the increase in phagocytosis and CD88 expression of RAW264.7 cells induced by GEN7G (Fig. 8B and C) .
Discussion
It was revealed for the first time that GEN7G enhanced phagocytosis and expressions of functional surface antigens in macrophages, and that intravenous administration of GEN7G enhanced phagocytosis of CD11b þ Ly6G À cells in the inflamed ears. The most important finding of the present study was confirmation of the consistent effects of GEN7G in vitro and in vivo because glucuronides have been generally recognized to be inactive. Our finding has raised the necessity of further study focusing on glucuronides as a carrier and precursor form of flavonoids. We concluded that the effects of GEN7G on macrophage functions depend on signaling via nuclear ERs, because (1) the enhancing activities of genistein, liquiritigenin, and hesperetin on macrophage phagocytosis were correlated to the binding activities to nuclear ERs [17] ; (2) the action of GEN7G was decreased by ICI-182780, which works as an antagonist of nuclear ERs and also as an agonist of membrane GPERs [19] ; (3) estradiol enhanced macrophage phagocytosis at similar concentrations as genistein and GEN7G; (4) GEN7G showed no agonistic activity toward GPR30 even at the high concentration of 100 mmol/L, and genistein reduced intracellular signals following b-arrestin recruitment, although some papers have demonstrated the agonism of genistein [20, 21] ; and (5) some flavonoids known as phytoestrogens enhance the phagocytic activity of myeloid leukemia cells and activate macrophage-like cells [22] [23] [24] [25] [26] [27] . Quantitative real-time PCR revealed that RAW264.7 cells dominantly expressed Esr1/ ERa, but not Esr2/ERb (Supplemental Fig. S3 ). The signal pathway through nuclear ERs in immune cells, especially dendritic cells, and macrophages, was reviewed recently, and ERs, in particular ERa, may induce epigenetic changes in immune precursor cells that affect the downstream developmental pathway or functional responses in mature cells [28] [29] [30] . Taken together, it is plausible to conclude that genistein/GEN7G promote macrophage function and differentiation through agonistic activity toward nuclear ERs and significantly involve innate immune systems (Fig. 9) . Contrary to the results of the present genistein/GEN7G study, several studies have demonstrated that various types of flavonoids inhibit macrophage activation [31] [32] [33] [34] . Genistein also affects multiple receptor signaling. Genistein is used as a tyrosine-kinase inhibitor and reported to reduce intracellular pro-inflammatory signals such as NF-kB [32, 35] . Genistein is reported to be an agonist for nuclear receptors like PPAR-g and progesterone receptor as well as estrogen receptors [17, 36, 37] . In our skin infection model, genistein/GEN7G enhanced CD11b þ Ly6G À tissue macrophages through ERs. Since genistein exerts profound effects and its function has multiple aspects in the inflammatory reaction, the precise analysis of macrophages types would be critical to understand the flavonoid action in inflammation. Due to the sugar group, glucuronides are at a disadvantage in passing through the plasma membrane and interact with nuclear ERs localized in the cytoplasm and nucleus. Macrophage b-glucuronidase is usually localized intracellularly in the lysosomes and appeared on cell surface, and released extracellularly by an increase of intracellular calcium ions, for example, LPS stimulation [32] . In our culture systems, a suboptimal dose of IFN-g was added to increase the sensitivity to flavonoids, and we detected b-glucuronidase in both supernatant and cell lysate of RAW264.7 cells. Therefore, the conversion of flavonoids can occur extracellularly, although intracellular conversion cannot be denied. The IC 50 of GEN7G was approximately a 1000-fold that of genistein in both ER1-and ER2-binding assays. Addition of a b-glucuronidase inhibitor completely suppressed the macrophage activation induced by GEN7G, though the conversion to genistein was reduced to half. As shown in Figure 2A , approximately 10 mmol/L of genistein was supposed to be the threshold concentration to activate macrophages. The b-glucuronidase inhibitor reduced the genistein conversion to less than the speculated threshold concentration of ca. 7 mmol/L (Fig. 8A) . Thus, the decrease in the genistein conversion to half might be enough to suppress macrophage activation completely by the b-glucuronidase inhibitor. Another b-glucuronidase inhibitor, saccharic acid 1,4-lactone, also suppressed macrophage activation A. Kaneko et al.
Flavonoid glucuronides activate macrophage induced by GEN7G (data not shown). These lines of evidence indicate that a deconjugation process is a critical step to gain GEN7G activities. The RAW264.7 cell is a line of immature macrophages. RAW264.7 cells showed a high potential to proliferate at least for one day after GEN7G stimulation, and cell proliferation gradually decreased after two to three days (data not shown). As shown in Figure 3 , morphological changes of RAW264.7 cells were observed after two to three days stimulation with genistein and GEN7G. Phagocytosis of FITC-conjugated bacteria was little at one-day stimulation with GEN7G, and two to three days were required to observe clear evidence of enhanced phagocytosis as well as expression of functional receptors in vitro ( Fig. 2 and Table 3 ). These observations suggest that genistein and GEN7G induce maturation of macrophages. On the other hand, phagocytosis of macrophages in the inflamed ears was significantly augmented at six hours after the first injection of GEN7G in vivo (Table 1) . In living mice, mature and activated macrophages already existed in tissue as resident macrophages before flavonoid administration, and excessive maturation of macrophages may lead to pyroptosis, followed Figure 9 . Possible mechanisms of macrophage activation by genistein 7-O-glucuronide. (1) GEN7G infiltrates to the inflamed sites through increased microvascular permeability; (2) GEN7G is exposed to resident macrophages and converted to genistein by b-glucuronidase of resident macrophages intra-and extracellularly; (3) thereafter, resident macrophages are more easily activated by genistein and GEN7G than neutrophils that accumulate later in the inflamed sites.
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by release of intracellular bioactive factors to evoke a fullfledged inflammatory response [38, 39] . Given that dead cell-derived extracellular b-glucuronidase is sufficient for deconjugation of GEN7G or that macrophages highly possessing b-glucuronidase are implicated in the inflamed sites, the appearance of GEN7G's effect would be observed quickly. The stages of macrophage maturation may also explain the time lag of enhanced phagocytosis by GEN7G between at two to three days in vitro and at six hours in vivo.
In the experiment shown in Figure 1 , the amount of intravenously injected GEN7G was almost same between in inflamed skin and in non-inflamed skin, or slightly lower in inflamed skin than in non-inflamed skin. In contrast, the amount of the deconjugated genistein was 2.5 times higher in the inflamed skin than in the non-injected skin. There is no doubt that GEN7G was metabolized to genistein in skin tissue, and the difference between GEN7G and genistein is supposed to result from inflammation-induced conditions in which b-glucuronidase works well. An increased vascular permeability is not enough to explain the difference.
The FACS analysis indicated enhancement of phagocytosis in FITC-positive CD11b þ Ly6G À cells, which are monocytes/macrophages ingesting FITC-conjugated bacteria. It was of interest that the activation by GEN7G was observed only in monocytes/macrophages but not in neutrophils. The increase of phagocytosis in monocytes/ macrophages was speculated to depend on resident macrophages because monocytes are known to have little phagocytic activity [15] . Along with stimulating the phagocytic function of resident macrophages, it is reported that b-glucuronidase is expressed in resident macrophages but not circulating blood cells [32] . Since we detected GEN7G after oral administration of JHT, we draw the dynamics of GEN7G as follows ( Fig. 9 ): (1) GEN7G infiltrates inflamed sites through increased microvascular permeability; (2) GEN7G is exposed to resident macrophages and converted to genistein by the b-glucuronidase of resident macrophages intra-and extracellularly; and (3) subsequently, resident macrophages are more easily activated by genistein and GEN7G than the neutrophils that accumulate later in the inflamed sites. In fact, genistein was found in the skin of mice given an intravenous injection of GEN7G. Generation of genistein by intravenous injection of GEN7G was higher in the inflamed ears than the noninflamed ears. The conversion of GEN7G to genistein was confirmed also by incubation with skin homogenizations of mouse ears (data not shown). These results raised a possibility that the diseased tissues or organs may be affected more effectively than normal tissue by flavonoid glucuronides, namely, orally administrated flavonoids. In general, aglycones are bioactive but unstable, while glucuronide conjugates are inactive but stable. Our data suggest that the macrophage-derived deconjugation plays an important role in transiently providing bioactive/unstable aglycones in the biological fluids, in particular, within the sites of inflammation. The selective deconjugation within the sites of inflammation might ensure the safety of flavonoids in normal tissues. From the standpoint of pharmacokinetic and metabolic studies, we clarified the mechanism by which orally administered flavonoids exhibit their pharmacological actions during inflammatory responses. Oral flavonoids could be inactivated once by a conjugation metabolism during absorption, delivered to the inflamed sites, exposed extracellularly or intracellularly to the b-glucuronidase of resident macrophages, converted to biologically active aglycones, and modify the inflammatory response (Fig. 9) . In the present study, we confirmed biological actions of flavonoid glucuronides, and that b-glucuronidase-possessing macrophages play a role in converting flavonoid glucuronides to active aglycones. Our study also demonstrated the actions of flavonoid glucuronides to enhance microbe phagocytosis by macrophages both in vitro and in vivo. While our study focused on adjuvant activity in innate immune cells, the inhibitory effect of flavonoids on skin inflammation may be valid and explained as well by our scenario of the deconjugation process. The present study elucidated a biologically interesting feature of glucuronides as a carrier and precursor form and would contribute to the pharmacological study of general glucuronides, not only flavonoid glucuronides. Further studies of the pharmacokinetics and metabolism of flavonoids will increase our understanding of how glucuronides exert profound effects on various tissues and diseases. 
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher's web-site. Figure S1 . Chemical structures of flavonoid glucuronides assayed in this study. Figure S2 . Representative dot-plots of phagocytic cells in the ears treated with or without intradermal injection of FITC-S. aureus particles in mice administered GEN7G or the vehicle. Particles of FITC-conjugated and killed S. aureus (67 mg/10 mL/site) were injected intradermally to the ears of mice. Genistein 7-O-glucuronide (GEN7G) dissolved in saline was administrated intravenously to the mice at a dose of 1 mg/10 mL/kg immediately and 3 h post the pseudoinfection. The ears were cut off at 6 h post the pseudoinfection, and digested in a mixture of three kinds of enzyme (dispase I, collagenase II, and DNase I) for 2 h in 378C, followed by preparation of single cells. Phagocytic cells were stained by anti-mouse Ly6G (APC-label) and anti-mouse CD11b (PE/Cy7 label), and analyzed by flow cytometer using FACSaria II system. The cells gated in R-1 region (CD11b Figure S3 . Gene expression of estrogen receptors in RAW264.7 cells. Total RNAs were prepared from proliferating RAW264.7 cells cultured in 24-well plates, followed by preparation of cDNAs. TaqMan gene expression assays were performed using TaqMan primers for Esr-1 (nuclear estrogen receptor-a), Esr-2 (nuclear estrogen receptor-b), and Gper1 (G protein-coupled estrogen receptor). All data are shown as relative to a housekeeping gene, Gapdh (glyceraldehyde-3-phosphate dehydrogenase). The primers of these targets were purchased from ABI Biosystems (Foster City, CA). N ¼ 2. ND: not detected showing 0.0001% to Gapdh.
